Got $2,500? Check Out These 2 Biotech 2.0 Stocks

Biotech 2.0 is here. Big data is an integral part of the drug development process in practically every corner of the industry. In contrast to the labor-intensive, slow, and small-scale nature of the traditional approach to drug development, the biotechs of the future are fusing computing power and laboratory experimentation, and the results will reshape what it means to make new medicines.

Today, I'll be discussing two of these front-running biotechs. Neither of them are profitable yet, and they won't be anytime soon. But they're both leveraging unique treasure troves of data to develop drugs in ways that no other company can replicate. So, while there's no guarantee that they'll turn your $2,500 investment into millions, they've got a better shot at doing so than a lot of the other options in biopharma. Let's take a look at why.

Image source: Getty Images.

Source Fool.com